Literature DB >> 21604711

Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Prasenjit Mukherjee1, Falgun Shah, Prashant Desai, Mitchell Avery.   

Abstract

SARS-CoV from the coronaviridae family has been identified as the etiological agent of Severe Acute Respiratory Syndrome (SARS), a highly contagious upper respiratory disease that reached epidemic status in 2002. SARS-3CL(pro), a cysteine protease indispensible to the viral life cycle, has been identified as one of the key therapeutic targets against SARS. A combined ligand and structure-based virtual screening was carried out against the Asinex Platinum collection. Multiple low micromolar inhibitors of the enzyme were identified through this search, one of which also showed activity against SARS-CoV in a whole cell CPE assay. Furthermore, multinanosecond explicit solvent simulations were carried out using the docking poses of the identified hits to study the overall stability of the binding site interactions as well as identify important changes in the interaction profile that were not apparent from the docking study. Cumulative analysis of the evaluated compounds and the simulation studies led to the identification of certain protein-ligand interaction patterns which would be useful in further structure based design efforts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21604711      PMCID: PMC3929308          DOI: 10.1021/ci1004916

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  95 in total

1.  In silico prediction of membrane permeability from calculated molecular parameters.

Authors:  Hanne H F Refsgaard; Berith F Jensen; Per B Brockhoff; Søren B Padkjaer; Mette Guldbrandt; Michael S Christensen
Journal:  J Med Chem       Date:  2005-02-10       Impact factor: 7.446

2.  A bioavailability score.

Authors:  Yvonne C Martin
Journal:  J Med Chem       Date:  2005-05-05       Impact factor: 7.446

3.  Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme.

Authors:  Kiira Ratia; Kumar Singh Saikatendu; Bernard D Santarsiero; Naina Barretto; Susan C Baker; Raymond C Stevens; Andrew D Mesecar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-31       Impact factor: 11.205

4.  Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.

Authors:  I-Lin Lu; Neeraj Mahindroo; Po-Huang Liang; Yi-Hui Peng; Chih-Jung Kuo; Keng-Chang Tsai; Hsing-Pang Hsieh; Yu-Sheng Chao; Su-Ying Wu
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

5.  Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.

Authors:  Syaulan Yang; Shu-Jen Chen; Min-Feng Hsu; Jen-Dar Wu; Chien-Te K Tseng; Yu-Fan Liu; Hua-Chien Chen; Chun-Wei Kuo; Chi-Shen Wu; Li-Wen Chang; Wen-Chang Chen; Shao-Ying Liao; Teng-Yuan Chang; Hsin-Hui Hung; Hui-Lin Shr; Cheng-Yuan Liu; Yu-An Huang; Ling-Yin Chang; Jen-Chi Hsu; Clarence J Peters; Andrew H-J Wang; Ming-Chu Hsu
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

6.  Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.

Authors:  Jiun-Jie Shie; Jim-Min Fang; Chih-Jung Kuo; Tun-Hsun Kuo; Po-Huang Liang; Hung-Jyun Huang; Wen-Bin Yang; Chun-Hung Lin; Jiun-Ling Chen; Yin-Ta Wu; Chi-Huey Wong
Journal:  J Med Chem       Date:  2005-06-30       Impact factor: 7.446

7.  Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.

Authors:  Lili Chen; Chunshan Gui; Xiaomin Luo; Qingang Yang; Stephan Günther; Elke Scandella; Christian Drosten; Donglu Bai; Xichang He; Burkhard Ludewig; Jing Chen; Haibin Luo; Yiming Yang; Yifu Yang; Jianping Zou; Volker Thiel; Kaixian Chen; Jianhua Shen; Xu Shen; Hualiang Jiang
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations.

Authors:  Danzhi Huang; Urs Lüthi; Peter Kolb; Karin Edler; Marco Cecchini; Stephan Audetat; Alcide Barberis; Amedeo Caflisch
Journal:  J Med Chem       Date:  2005-08-11       Impact factor: 7.446

9.  Mechanism of the maturation process of SARS-CoV 3CL protease.

Authors:  Min-Feng Hsu; Chih-Jung Kuo; Kai-Ti Chang; Hui-Chuan Chang; Chia-Cheng Chou; Tzu-Ping Ko; Hui-Lin Shr; Gu-Gang Chang; Andrew H-J Wang; Po-Huang Liang
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

10.  Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer.

Authors:  Ting Xu; Amy Ooi; Hooi Chen Lee; Rupert Wilmouth; Ding Xiang Liu; Julien Lescar
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-10-20
View more
  14 in total

1.  An in silico protocol for identifying mTOR inhibitors from natural products.

Authors:  Lei Chen; Ling Wang; Qiong Gu; Jun Xu
Journal:  Mol Divers       Date:  2014-08-26       Impact factor: 2.943

2.  In Silico Drug Discovery for Treatment of Virus Diseases.

Authors:  Shikha Joon; Rajeev K Singla; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Recent progress in the discovery of inhibitors targeting coronavirus proteases.

Authors:  Haofeng Wang; Song Xue; Haitao Yang; Cheng Chen
Journal:  Virol Sin       Date:  2016-02-19       Impact factor: 4.327

4.  Synthesis and Biological Evaluation of Quinolinone Compounds as SARS CoV 3CLpro Inhibitors.

Authors:  Yuanpei Sun; Ning Zhang; Jian Wang; Yu Guo; Bo Sun; Wei Liu; Honggang Zhou; Cheng Yang
Journal:  Chin J Chem       Date:  2013-07-19       Impact factor: 6.000

Review 5.  Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection.

Authors:  Manashjyoti Konwar; Diganta Sarma
Journal:  Tetrahedron       Date:  2020-11-19       Impact factor: 2.457

Review 6.  A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).

Authors:  Maryam Rameshrad; Majid Ghafoori; Amir Hooshang Mohammadpour; Mohammad Javad Dehghan Nayeri; Hossein Hosseinzadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-05-19       Impact factor: 3.000

7.  In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.

Authors:  Deng-Hai Zhang; Kun-Lun Wu; Xue Zhang; Sheng-Qiong Deng; Bin Peng
Journal:  J Integr Med       Date:  2020-02-20

8.  Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MSE analysis.

Authors:  Zi-Jia Zhang; Wen-Yong Wu; Jin-Jun Hou; Lin-Lin Zhang; Fei-Fei Li; Lei Gao; Xing-Dong Wu; Jing-Ying Shi; Rong Zhang; Hua-Li Long; Min Lei; Wan-Ying Wu; De-An Guo; Kai-Xian Chen; Lewis A Hofmann; Zhong-Hua Ci
Journal:  J Integr Med       Date:  2020-04-08

9.  Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.

Authors:  Bodee Nutho; Panupong Mahalapbutr; Kowit Hengphasatporn; Nawanwat Chainuwong Pattaranggoon; Nattapon Simanon; Yasuteru Shigeta; Supot Hannongbua; Thanyada Rungrotmongkol
Journal:  Biochemistry       Date:  2020-04-24       Impact factor: 3.162

10.  In silico virtual screening approaches for anti-viral drug discovery.

Authors:  Manuela S Murgueitio; Marcel Bermudez; Jérémie Mortier; Gerhard Wolber
Journal:  Drug Discov Today Technol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.